Introduction {#sec1-1}
============

Since being introduced in 1999, drug eluting stents (DES) have revolutionized the treatment of coronary artery disease. Compared to bare metal stents (BMS), DES have led to dramatic reductions in the rates of restenosis and repeat revascularizations, while improving target lesion revascularization (TLR)[@ref1]--[@ref4]. In recent years, concern has been raised regarding the long-term safety of DES and the risk of late restenosis and stent thrombosis (ST). This potential increased risk remains an area of uncertainty in the field of cardiology. The goal of this review will be to help clarify some of the controversies surrounding DES use, including newer stent technology, in-stent restenosis, ST risk, the role of genetic testing and platelet function assays and outcomes in "off-label" indications.

First generation DES {#sec1-2}
====================

The first generation DES include Cypher (Cordis, Bridgewater, NJ) and Taxus stents (Boston Scientific, Nantick, MA). These stents consist of a stainless steel platform, a non-erodible permanent polymer coating and an anti-restenotic drug. The Cypher stents release sirolimus, a macrolide antibiotic that inhibits neointimal proliferation, while the Taxus stents release paclitaxel, a chemotherapeutic agent that suppresses cell mitosis[@ref5][@ref6].

The landmark RAVEL (Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with *De Novo* Native Coronary Artery Lesions) trial was the first randomized study comparing sirolimus-eluting stents (SES) with BMS in patients undergoing percutaneous intervention (PCI) for simple lesions. At 1 year, the rates of restenosis were 0% for the SES group and 26.6 per cent for the BMS group[@ref7]. These findings were confirmed in the SIRIUS trial, which showed a dramatic reduction in restenosis rates in more complex lesions treated with SES compared to BMS (3.2 vs. 35.4%; *P*\<0.001)[@ref8].

Similar to the SES, randomized trials have demonstrated the superiority of paclitaxel-eluting stents (PES) over BMS. The pivotal approval trial, TAXUS IV, found significantly lower rates of in-stent restenosis in single lesions treated with PES compared to BMS at 9 month angiographic follow up (5.5 vs. 24.4%; *P*\<0.0001)[@ref9]. Subsequent randomized trials and meta-analyses have confirmed these findings across different patient subgroups and lesion characteristics[@ref2][@ref3][@ref9]--[@ref13].

These extraordinary results demonstrating profound reductions in restenosis rates associated with SES and PES led to the widespread adoption of the first generation DES for both "on-label" and "off-label use." In the mid 2000s however, reports began to surface regarding increased mortality associated with DES compared to BMS. Results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), reported significantly increased mortality rates associated with DES from 6 month to 3 year follow up (adjusted RR 1.32; 95% CI: 1.11-1.57)[@ref14]. These results, along with reports of ST, a rare but serious complication of coronary artery stents, raised concern regarding the overall safety profile of DES[@ref15]. Originally presented in 2005 and later published in 2006, Barvy and colleagues[@ref16] reported a significantly increased risk of late ST associated with DES use. This meta-analysis, which included 14 clinical trials consisting of almost 6675 patients with relatively simple lesions, noted a 4 to 5-fold increased late ST risk in DES compared to BMS (RR = 5.02; 95% CI: 1.29-35.45; *P*=0.02)[@ref16]. The median time for ST was also significantly later in the DES group compared to the BMS group (18 vs. 3.5 months; *P*=0.0003). These findings were confirmed by Stone and colleagues[@ref4], who performed a pooled analysis from randomized, double blind trials comparing the first generation DES with BMS. From stent placement to 4 year follow up, the overall rates of ST among SES (1.2 vs. 0.6%; *P*=0.20) and PES (1.3 vs. 0.9%; *P*=0.30) were similar to BMS. Between 1 and 4 years however, the rates of ST in both the SES (0.6 vs. 0%; *P*=0.025) and PES (0.7 vs. 0.2%; *P*=0.028) groups were significantly higher compared to BMS[@ref4] ([Fig. 1](#F1){ref-type="fig"}).
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Other studies have corroborated the increased ST risk after 1 year associated with the first generation DES. In a large, collaborative meta-analysis using the Academic Research Consortium (ARC) definitions of ST, no difference was noted in the rates of early ST (\<30 days) or late ST (30 days to 1 year) between the first generation DES and BMS. The rates of very late ST (\>1 yr), however, was significantly higher in SES and PES when compared to BMS (0.7 vs. 0.1%; *P*= 0.006)[@ref17]. In the j-Cypher study, a multicenter prospective registry of consecutive patients undergoing SES implantation in Japan, the overall cumulative rates of definite ST with SES were low (30 day =0.3%; 1 yr = 0.6%; and 5 yr =1.6%). The rates of late and very late ST, however, continued to rise without attenuation out to 5 years of follow up[@ref18].

One of the proposed mechanisms associated with increased ST risk beyond 1 year in the first generation DES, surrounds the permanent polymer coatings that assist in anti-restenotic drug release. Histopathology studies have demonstrated these permanent polymers result in delayed healing, impaired endothelialization and hypersensitivity reactions that likely contribute to the increased risk of ST[@ref19]--[@ref23]. Over the last 5 to 7 years, this increased ST risk associated with DES, has been a cause for concern in the field of interventional cardiology.

In addition to the risk of ST, recent concern regarding DES efficacy has focused on the rates of late and very late restenosis. The initial trials comparing the first generation DES with BMS found less than 6 per cent restenosis in patients treated with SES or PES[@ref8][@ref9]. Despite these remarkable results, attention has been directed to the area of long-term outcomes associated with restenosis. A prospective, systematic study by Bryne and colleagues[@ref24], reported rates of delayed, in-segment binary restenosis of 12.1 per cent in lesions treated with SES and 17.2 per cent in lesions treated with PES at 2 year angiographic follow up[@ref24]. Other single center and registry studies also reported rates of late restenosis greater than 10 per cent in patients treated with first generation DES[@ref24]--[@ref27]. A recently published study from the j-Cypher registry[@ref18], found that patients treated with SES demonstrated cumulative indices of TLR of 15.9 per cent at 5 years. From the time of stent implantation out to 5 years, these restenosis events rose at a rate of 2.2 per cent per year without attenuation[@ref18]. These results from the j-Cypher registry differs from the clinical course of BMS, which demonstrate an early restenosis phase (until 6 months), an intermediate regression phase (6 months to 3 years) and a late luminal re-narrowing phase (beyond 4 years)[@ref28]. In an attempt to improve the long term safety and efficacy of DES, research has focused on the development of new polymers and stent platforms to minimize restenosis and reduce ST risk.

Second generation DES {#sec1-3}
=====================

The second generation DES include the Endeavor (Medtronic, Minneapolis, MN, USA), Resolute (Medtronic), Xience V (Abbot Vascular, Santa Clara, CA, USA) and Promus (Boston Scientific, USA) stents and utilize a more biocompatible, non-erodible polymer. The Endeavor, second generation stents utilize a cobalt-chromium (CoCr) platform and a permanent phorylcholine polymer that facilitates the release of the sirolimus analogue, zotarolimus. Although not biodegradable, this biocompatible polymer releases 95 per cent of zotarolimus within 14 days. Both animal and *in vivo* studies have demonstrated less inflammation and greater endothelial stent strut coverage with zotarolimus eluting stents (ZES) compared with SES and PES[@ref29]--[@ref31]. Clinical data from the ENDEAVOR I and II studies reported significantly lower in-stent late loss, binary restenosis and TLR with ZES compared to BMS[@ref32][@ref33]. Additionally, rates of death, myocardial infarction (MI) and ST remained similar to BMS out to 5 years of follow up.

The Resolute ZES utilizes a CoCr stent platform designed in a continuous, sinusoidal-helical pattern. Additionally, a biocompatible BioLinx polymer, facilitates the extended release of 85 per cent of zotarolimus within 60 days and almost 100 per cent by 180 days[@ref34]. The results from the prospective, observational RESOLUTE US trial, which enrolled 1402 patients with *de novo* native coronary lesions, demonstrated 12 month rates of target lesion failure (TLF) of 3.7 per cent in patients receiving the Resolute ZES compared to 6.5 per cent in historical Endeavor ZES controls (p~noninferiority~ \< 0.001; post-hoc p~superiority~ = 0.002). Overall clinical outcomes additionally demonstrated low rates of cardiac death (0.4%), MI (1.3%), TLR (2.0%) and ST (0.1%). The prevalence of diabetes in the RESOLUTE US population was 34.4 per cent, with prespecified diabetic subgroup analysis demonstrating low rates of TLF (4.3%), cardiac death (0.5%), MI (0.8%) and TLR (3.0%)[@ref35]. These findings were confirmed in the RESOLUTE All Comers trial and the TWENTE trial, which reported non-inferiority between the Resolute ZES and everolimus-eluting stents (EES) at 1 and 2 year follow up[@ref36]--[@ref38]. Based on these findings, on February 17, 2012, the U.S. Food and Drug Administration (FDA) approved the Resolute ZES for use in *de novo* coronary lesions and diabetic patients, becoming the first stent gaining an "on-label" indication for this population[@ref39].

Xience V and Promus stents elute everolimus, an antiproliferative agent in the same family as sirolimus. Attached to a CoCr or platinum-chromium (PtCr) stent platform, is a biocompatible polymer that assists in the release of approximately 80 per cent of everolimus within 30 days and almost 100 per cent within 4 months[@ref5].

The safety and efficacy of the EES when compared to BMS, have been demonstrated in the SPIRIT I, II and III randomized trials[@ref40]--[@ref42]. Additionally, in the recently published SPIRIT IV trial which randomized 3690 patients undergoing PCI to either Xience V EES or Taxus Express PES, the EES arm demonstrated significantly better rates of TLF (4.2 vs. 6.8%; *P*=0.001) and major adverse cardiac events (MACE) (4.2 vs. 6.9%; *P*= 0.0009) at 1 year[@ref43]. The superiority of EES was also demonstrated in the area of ischaemia-driven TLR (2.5 vs. 4.6%; *P*=001), target vessel MI (1.8 vs. 2.9%; *P*=0.04) and definite/probable ST (0.29 vs. 1.10%; *P*=0.004) ([Fig. 2](#F2){ref-type="fig"})[@ref42].

The strength of evidence supporting the clinical efficacy of EES is also supported by data from the COMPARE trial, which randomized 1800 patients undergoing coronary intervention to receive either Xience V EES or Taxus Liberte PES[@ref44]. This real world study reported better rates of MACE (6.2 vs. 9.1%; *P*=0.02) and target vessel revascularization (TVR) (2 vs. 6%; *P*=0.0001), again demonstrating the superiority of EES. Confirming these findings was a recently published meta-analysis by Baber and colleagues[@ref44], which identified 13 randomized trials comparing EES and non-EES DES. At a mean follow up of 21.7 months (range of 9-48 months), EES were superior to non-EES DES in the area of definite/probable ST (0.7 vs. 1.5%; *P*=0.001), MI (2.9 vs. 3.9%; *P*=0.002) and TVR (5.7 vs. 7.7%; *P*= 0.004), with no difference in cardiac mortality (1.6 vs. 1.9%; *P*=0.38). In sensitivity analyses, the overall superiority of EES persisted for the endpoints of ST, TVR and MI regardless of clopidogrel duration (6 or 12 months) or duration of follow up (≤1 yr or \>1 yr)[@ref45].
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A recently published network meta-analysis that involved 49 randomized trials and 50,844 patients provided further evidence into the superiority of EES, particularly those with CoCr stent platforms[@ref46]. When compared to BMS, rates of ST were significantly lower at 1 year (OR: 023; 95% CI: 0.13-0.41) and 2 year follow up (OR: 0.35; 95% CI: 0.17-0.69). These findings are in stark contrast to the widely held notion regarding increased late and very late ST risk associated with DES. Additionally, CoCr-EES were also associated with less ST at 1 year compared to PES (OR: 028; 95% CI: 0.16-0.48), SES (OR: 0.41; 95% CI: 0.24-0.0.70) and ZES (OR: 0.21; 95% CI: 0.10-0.44). The second generation DES, particularly CoCr-EES appear to have improved safety and efficacy profiles compared to not only BMS but also the first generation DES.

Bioabsorbable polymers {#sec1-4}
======================

The biocompatible polymer coatings on the first and second generation DES are effective in facilitating anti-proliferative drug release. It is thought that the more biocompatible polymers on the second generation DES offer less inflammation and a greater degree of re-endothelialization compared with the first generation DES. Despite these improvements, the second generation polymers persist for many years and may play a significant role in the occurrence of late and very late ST events[@ref47]--[@ref49]. Because of this, extensive research is currently underway in the development of fully bioabsorbable polymers that not only offer control of drug delivery but also avoid the long-term issues related to the presence of residual polymers. There have been many biodegradable polymers developed over the last few years, but questions and controversy remain regarding if this technology will result in improved clinical outcomes.

The all-comers Limus Eluted from a Durable Versus Erodible Stent Coating (LEADERS) trial[@ref49][@ref50], evaluated the BioMatrix stent (Biosensors International, Singapore), which utilizes a sirolimus analogue (Biolimus A9) and a biodegradable polylactic acid (PLA) polymer that completely dissolves over a 6 to 9 month period. This trial, which enrolled 1707 patients, demonstrated that the BioMatrix stent was non-inferior to Cypher SES in the area of MACE, (10.6 vs. 12.0%; *P*=0.37)[@ref50][@ref51]. A second trial, NEVO RES-ELUTION I[@ref52], evaluated the NEVO sirolimus-eluting stent system with a bioabsorbable polylactic-glycolic acid (PLGA) polymer (Cordis, Bridgewater, NJ, USA) that completely degrades in 3 to 4 months. This study, which randomized patients to either the NEVO SES or Taxus Liberte PES, demonstrated significantly lower rates of in-stent late loss in patients treated with the bioabsorbable polymer (0.13 ± 0.31 vs. 0.36 ± 0.46 mm; *P*\<0.001)[@ref52].

Additionally, the recently published Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents-4 (ISAR TEST 4) trial reported outcomes among 2603 patients randomized to receive either a SES with a novel bioabsorbable polymer, a standard Cypher SES or a Xience V EES. Three-year follow up data found non-inferiority in the combined endpoints of cardiac death, target vessel MI or TLR in the bioabsorbable polymer compared to Cypher or Xience V stents (20.1 vs. 20.9%; *P*=0.59). There also was no statistically significant difference in the endpoints of definite/probable ST (1.2 vs. 1.7%; *P*=0.32) or TLR (13.9 vs. 14.2%; *P*=0.79)[@ref53][@ref54] ([Fig. 3](#F3){ref-type="fig"}).
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Newer technology including polymer-free and fully bioabsorbable DES are currently under various stages of development with future studies upcoming. This future step forward represents the next generation of DES and offer the possibility of minimizing ST risk and the need for long-term dual antiplatelet therapy (DAPT), while maximizing revascularization for coronary artery disease.

Antiplatelet therapy {#sec1-5}
====================

Current guidelines on the use of DES, recommend DAPT consisting of aspirin and a thienopyridine. Clopidogrel, the most widely used thienopyridine, works by inhibiting the P2Y12 platelet receptor, thereby interfering with ADP-induced platelet activation and aggregation[@ref55]. Multiple studies have demonstrated that treatment with DAPT significantly reduce cardiac events after DES implantation[@ref56]--[@ref59]. In addition to clopidogrel, other currently approved thienopyridines include prasugrel and ticagrelor.

One controversy that has come to attention since the development and implementation of DES is related to the optimal duration of DAPT. Initial studies demonstrating the efficacy of the first generation DES maintained clopidogrel therapy for 3 to 6 months after stent implantation[@ref8][@ref9]. Soon after these landmark trials were published, case reports began to surface of angiographically documented ST that occurred 343 to 442 days after DES implantation[@ref60]. In all cases, ST occurred soon after antiplatelet therapy was discontinued[@ref60]. Further retrospective studies revealed that the discontinuation of clopidogrel, even more than 6 months after DES implantation, was associated with increased ST risk[@ref60]--[@ref63]. These findings were supported by results from a substudy of the Basel Stent Kosten Effetivtats Trial- Late Thrombotic Events (BASKET-LATE) trial, which was conducted to determine the incidence of late clinical events in patients treated with DES compared to BMS. After clopidogrel discontinuation, late ST-related events were 2 to 3 times more frequent in the DES group compared to the BMS group[@ref64]. Based on these studies, the ACCF/AHA/SCAI released guidelines for percutaneous coronary interventions in 2011 that recommend 12 months of thienopyridine treatment after DES implantation[@ref65]. Currently, no guidelines exist regarding the continuation of thienopyridine therapy in patients with DES beyond 1 year.

Results from several recent trials involving the Endeavor ZES have demonstrated favourable safety and efficacy profiles despite shorter durations of DAPT. In the DATE (Duration of Dual Antiplatelet Therapy after Implantation of Endeavor Stent) Registry, 823 patients were enrolled to either 3 months or greater than 3 months of DAPT after PCI with the Endeavor ZES[@ref66]. At 1 year follow up, there were no significant difference in the composite endpoint of cardiac death, MI or ST between both treatment groups (0.5 vs. 0.7%; *P*=0.93). The results of the larger RESET (Real Safety and Efficacy of a 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation) trial, which assessed shorter durations of DAPT was presented at the American College of Cardiology (ACC) 2012 Scientific Sessions[@ref67]. This study, which randomized 2148 patient undergoing PCI with ZES to either 3 months or 12 months of DAPT, found no significant difference in the composite endpoint of all-cause mortality, MI or ST (1.3 vs. 0.8%; *P*=0.48)[@ref67]. Additional findings noted no difference in rates of ST (0.2 vs. 0.3%; *P*=0.65), MI (0.2 vs. 0.4%; *P*=0.41), TVR (3.9 vs. 3.7%; *P*=0.70) or major/minor bleeding (0.5 vs. 1.0%; *P*=0.20) between both the short (3 months) and standard (12 month) duration of DAPT. The results of these studies suggest that a shorter duration of DAPT may be appropriate in relatively lower risk patients who undergo stenting with ZES. These findings have important implications especially in patients with increased bleeding risks, medication compliance issues or those who require future surgery or procedures that require interruption of DAPT.

In order to better understand the optimal duration of antiplatelet therapy, Mauri and colleagues are currently conducting a trial that will randomize over 15,000 patients to receive either 12 or 30 months of aspirin plus thienopyridine therapy after PCI. The goal of the Dual Antiplatelet Therapy (DAPT) study is to determine the safety and effectiveness of continuing antiplatelet therapy beyond the recommended 12 month duration[@ref68]. Another study currently in progress utilizes platelet responsiveness testing in order to determine the optimal duration of antiplatelet therapy[@ref68]. The goal of the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) registry will be to determine the relationship between platelet responsiveness testing using the VerifyNow P2Y12 assay and the occurrence of late and very late ST events in patients who have continued or discontinued thienopyridine and aspirin therapy after DES implantation. The 30 day results of the ADAPT-DES registry were recently presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium[@ref69]. At 30 days, the absolute and relative levels of platelet responsiveness were independent predictors of ST with a significant number of events directly attributed to clopidogrel hypo-responsiveness. Given the generally low levels of ST along with the relatively modest sensitivity and specificity of platelet function assays, the authors concluded that platelet responsiveness was unlikely to provide information to guide decision making for the prevention of ST at 30 days.

Other antiplatelet agents currently under investigation include the intravenous P2Y12 receptor antagonist, cangrelor and the protease-activated receptor (PAR-1) inhibitor, vorapaxar. Pharmacologic studies of cangrelor demonstrate immediate and potent platelet inhibition[@ref70]. Because of a relatively short half-life (3-6 min), this agent has the added benefit of rapid reversibility[@ref71]. The safety and efficacy of cangrelor was recently assessed in two trials that resulted from the CHAMPION (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) program. The CHAMPION PLATFORM trial randomized 5362 patients presenting with ACS to intravenous cangrelor or placebo at the time of PCI[@ref71]. All patients received 600 mg of clopidogrel, in addition to standard MI care. At 48 h, there was no significant difference in the composite endpoint of death, MI or ischaemia-driven revascularization between both treatment groups (7.0 vs. 8.0%; *P*= 0.17). The cangrelor group however, demonstrated lower rates of the pre-specified secondary endpoints of ST (0.2 vs. 0.6%; OR: 0.31; 95% CI 0.11-0.85; *P*=0.02) and all-cause mortality (0.2 vs. 0.7%; OR: 0.33; 95% CI 0.13-0.83; *P*=0.02) with no difference in the rate of blood transfusions (0.6 vs. 1.0%; *P*=0.13). Complimentary to the CHAMPION PLATFORM, the CHAMPION PCI trial randomized 8877 patients to intravenous cangrelor or oral clopidogrel (600 mg) prior to PCI[@ref72]. At 48 h, there was no difference in the composite endpoint of death, MI or ischaemia-driven revascularization (7.5 vs. 7.1%; OR: 1.05; 95% CI 0.88-1.24; *P*=0.59), need for blood transfusions (1.1 vs. 1.0%; *P*=0.68), groin hematoma \>5 cm (1.9 vs. 1.7%; *P*=0.48) or Thrombolysis in Myocardial Infraction (TIMI) major bleeding (0.4 vs. 0.3%; *P*=0.35) between both groups. One of the controversies regarding the results of the CHAMPION PLATFORM and CHAMPION PCI trials was with the challenges identifying post-procedure MIs. Because of this, White and colleagues[@ref71] performed a pooled analysis of the CHAMPION trials using the universal MI definition[@ref73]. This definition requires stable cardiac biomarkers prior to PCI with a new or recurrent myocardial infarction identified by a subsequent rise in cardiac troponin, creatine kinase (CK) or CK-MB isozyme \>3 times the 99^th^ percentile upper limit of normal. Using this universal definition, cangrelor was associated with a significant reduction in the composite endpoint of death, MI or ischaemia-driven revascularization at 48 h compared to a 600 mg loading dose of clopidogrel given either before or early after PCI in patients presenting with acute coronary syndrome (ACS) (OR: 0.82; 95% CI 0.68-0.99; *P*=0.037). Additionally, there was a significant reduction in ST (OR: 0.44; 95% CI 0.22-0.87; *P*=0.018) with no difference in TIMI major bleeding (0.3 vs. 0.3%; OR: 1.0; 95% CI 0.56-1.78; *P*=0.99) or need for blood transfusions (1.0 vs. 0.8%; OR: 1.24; 95% CI 0.88-1.76; *P*=0.22).

Given the short half-life and rapid reversibility of cangrelor, there has been substantial interest in using this antiplatelet agent prior to surgery. In order to assess the effect of cangrelor for bridging thienopyridine-treated patients awaiting cardiac surgery, Angiolillo and colleagues performed an open-label, prospective, randomized trial comparing this intravenous P2Y12 receptor antagonist to placebo in patients with ACS or treated with a coronary stent awaiting coronary artery bypass graft (CABG)[@ref75]. The results of the BRIDGE (Maintenance of Platelet Inhibition with Cangrelor after Discontinuation of Thienopyridines in Patients Undergoing Surgery) Trial, reported a significantly greater degree of platelet inhibition in the cangrelor group with no difference in major bleeding prior to CABG. Cangrelor, although not yet FDA approved, has the potential to provide potent platelet inhibition, especially in patients unable to take oral thienopyridines or those requiring rapid reversibility prior to early CABG or other surgery[@ref71]--[@ref73].

Vorapaxar, a PAR-1 inhibitor represents a novel class of antiplatelet agent that inhibits thrombin-mediated platelet activation. Preclinical and phase 2 studies in patients with CAD support the potential of these drugs to improve clinical outcomes[@ref75]. The results of the large, multinational, double blind, placebo-controlled trial evaluating vorapaxar in the prevention of adverse cardiac events was recently presented at the ACC 2012 Scientific Sessions[@ref76]. The TRA 2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events- Thrombolysis in Myocardial Infarction 50) trial, involved 26,449 patients with underlying cardiovascular disease. At 3 years, patients treated with vorapaxar demonstrated a significant reduction in the composite endpoint of cardiovascular death, MI or stroke compared to placebo (9.3 vs. 10.5%; HR: 0.87; 95% CI 0.80-0.94; *P*\<0.001). Treatment with vorapaxar however, resulted in significantly more bleeding events compared to the placebo (4.2 vs. 2.5%; HR 1.66; 95% CI 1.43-1.93; *P*\<0.001)[@ref77]. A second trial assessing vorapaxar in the treatment of ACS found no significant difference in the composite endpoint of cardiovascular death, MI, stroke, recurrent ischaemia or urgent coronary revascularization compared to placebo (18.5 vs. 19.9%; HR: 0.92; 95% CI 0.85-1.01; *P*=0.07). Rates of moderate and severe bleeding were additionally higher in the vorapaxar group compared to the control group (7.2 vs. 5.2%; HR: 1.35; 95% CI 1.16-1.58; *P*\<0.001)[@ref78]. The specific role of PAR-1 inhibitors in the era of DES are currently under investigation and offer a potential to expand treatment options for patients undergoing coronary intervention. Future large scale trials are needed to define the specific role of vorapaxar and other PAR-1 receptor inhibitors.

Genetic testing {#sec1-6}
===============

Clopidogrel is a prodrug, activated by cytochrome P450 2C19 (CYP2C19) to an active metabolite that inhibits ADP-induced platelet aggregation[@ref80]. Pharmacogenetic and pharmacodynamic studies have demonstrated wide inter-individual variability in the metabolism and degree of platelet inhibition associated with clopidogrel[@ref79]--[@ref82]. Additionally, many genetic variations affecting clopidogrel metabolism have been discovered[@ref83]--[@ref86]. It is estimated that 5 to 30 per cent of all patients are poor metabolizers of clopidogrel, which could lead to adverse events after stent placement[@ref80][@ref87]. Patients with high on-treatment platelet reactivity despite clopidogrel, therefore, may have an increased risk of cardiovascular events including ST after PCI[@ref88].

To evaluate this concern, Mega and colleagues performed a meta-analysis that identified nine genetic studies evaluating the CYP2C19 genotype in patients treated with clopidogrel[@ref89]. Among the 9685 patients included in this study, 6937 (71.5%) were non-carriers, 2544 (26.3%) had one reduced-function CYP2C19 allele and 218 (2.2%) had two reduced function CYP2C19 alleles. Compared to non-carriers, patients with one reduced function allele had a significantly increased risk of the composite endpoint of cardiovascular death, myocardial infarction or stroke (HR: 1.55; 95% CI: 1.11-2.17; *P*=0.01). In patients who carried two reduced function alleles, there was an even greater risk of the composite endpoint compared to non-carriers (HR: 1.76; 95% CI: 1.24-2.50; *P*=0.002). In terms of ST, carriers of one reduced function CYP2C19 allele (HR: 2.67; 95% CI: 1.67-4.22; *P*=0.001) and carriers of two alleles (HR: 3.97; 95% CI: 1.75-9.02; *P*=0.001) were at significantly increased risk for ST when compared to non-carriers. Based on this meta-analysis and other studies that identified an increased cardiovascular risk associated with carriers of the CYP2C19 genotype, the FDA issued an alert recommending the consideration of CYP2C19 genetic testing in patients undergoing PCI and clopidogrel therapy[@ref90].

To further appraise the data on the association between clopidogrel responsiveness and CYP2C19 polymorphisms, Holmes and colleagues performed a systematic review and meta-analysis that came to different conclusions from the study by Mega *et al*[@ref91]. This study identified 32 trials that included 42,016 patients who underwent genetic testing for the loss of function CYP2C19 genotype. In a treatment-only analysis of 22 prospective observational studies and four randomized trials, individuals with any copy of a reduced function CYP2C19 allele had a significantly increased risk of cardiovascular events (RR: 1.18; 95% CI: 1.09-1.28). Due to evidence of small study bias, the analysis was restricted to larger studies (\>200 outcome events), with subsequent analysis demonstrating a smaller and non-significant effect associated with the CYP2C19 genotype (RR: 0.97; 95% CI: 0.86-1.09). Of all clinical outcomes, ST was most strongly associated with one or more loss of function CYP2C19 alleles (RR: 1.75; 95% CI: 1.5-2.03). The authors concluded that although an association between the CYP2C19 genotype and responsiveness to clopidogrel exists, there was no association between this polymorphism and cardiovascular events with the exception of ST.

These results appear to contradict the earlier meta-analysis published by Mega *et al*, and has subsequently generated considerable controversy regarding the interpretation and conclusions reached. Some of the major concerns relate to the inclusion of a large number of patients who did not undergo coronary stenting, the varied clopidogrel dosing (particularly loading dose) and the clinical endpoints included in this meta-analysis. The decreased emphasis on ST risk was also a problem to some, given the devastating consequences of ST. Although the absolute risk increase of 14 events per 1000 individuals in clopidogrel non-responders may seem relatively low, if this number is extrapolated to all the patients undergoing PCI, there could be thousands of additional ST events per year[@ref92]. Given these conflicting findings and to assist healthcare providers incorporate the FDA warning into clinical practice, the ACC and AHA released a clinical alert that argued against routine genetic testing prior to clopidogrel initiation due to lack of evidence[@ref93]. These recommendations differ from the FDA advisory and therefore, the use of genetic testing to identify individuals with the CYP2C19 genotype remains an area of uncertainty in the field of cardiology.

Platelet function testing {#sec1-7}
=========================

Several small studies have suggested that platelet reactivity assays are superior to genetic testing in identifying patients who are poor clopidogrel responders[@ref94]. These assays utilize light transmission aggregometry (LTA) to test platelet aggregation and activation in response to an ADP agonist[@ref95]. The POPULAR (Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel- Pretreated Patients Undergoing Elective PCI) study was designed to evaluate the ability of six platelet function tests to predict thrombotic events including ST, in clopidogrel treated patient undergoing coronary interventions. Of the assays evaluated, high on-treatment platelet reactivity evaluated by the VerifyNow P2Y12 (Accumetrics, San Diego, CA, USA), Plateletworks (Helena Laboratories, Beaumont, TX, USA) and Innovance PFA P2Y system (Siemens, Tarrytown, NY, USA), were associated with the composite endpoint of all-cause mortality, non-fatal MI, ST and ischaemic CVA[@ref96].

Further evaluation of the efficacy of platelet function assays were carried out by Brar and colleges, who identified six studies utilizing the VerifyNow P2Y12 assay shortly after percutaneous intervention[@ref97]. After grouping platelet reactivity unit (PRU) values into quartiles (quartile I representing the lowest on-treatment platelet reactivity and quartile IV representing the highest on-treatment platelet reactivity), pair-wise comparisons were performed using quartile I as the reference. Subjects with the highest on-treatment PRU values (quartile III and quartile IV), demonstrated the greatest risk of the composite endpoint of death, MI or ST (quartile III- HR: 1.82; 95% CI: 1.2-2.75 and quartile IV- HR 2.62; 95% CI: 1.77-3.87). When analysis was performed on a continuous scale, every 10 unit increase in PRU value was associated with a 4 per cent increase in the composite endpoint. In terms of ST, event rates were significantly greater in quartile IV compared to quartile I (3.4% vs. 0.4%; *P*=0.002). Utilizing receiver operating characteristic (ROC) analysis, a PRU value of 230 units or more was most accurate in predicting the composite endpoint of death, MI or ST. When this value was used to group patients into high (PRU ≥ 230) or normal (PRU \<230) on-treatment platelet reactivity, the high reactivity group had significantly greater event rates (HR: 2.10; 95% CI: 1.62-2.73, *P*\<0.0001) and mortality rates (HR: 1.66; 95% CI: 1.50-6.46; *P*=0.002) when compared to the normal platelet reactivity group. This increased risk associated with high on-treatment platelet reactivity remained significant, even after adjusting for age, gender, the presence of ACS or stent choice (DES or BMS)[@ref94].

The GRAVITAS (Gauging Responsiveness with A VerifyNow Assay- Impact on Thrombosis and Safety) trial was designed to determine whether increasing the maintenance dose of clopidogrel can overcome platelet non-responsiveness based on the VerifyNow assay[@ref98]. This trial, randomized 2214 patients undergoing PCI with high on-treatment platelet reactivity (PRU ≥ 230) to standard (75 mg daily) versus high (150 mg daily) clopidogrel maintenance dosing. At 6 month follow up, the reduction in platelet reactivity based on the VerifyNow assay was significantly greater in the high clopidogrel dosing group compared to standard clopidogrel dosing group (80 vs. 37 PRU; P\<0.0001). Despite the reduction in platelet reactivity, there was no significant difference in the composite endpoint of cardiovascular death, MI or ST (2.3 vs. 2.3%; *P*=0.98).

These findings were supported by the TRIGGER PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel) trial, which was presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 Scientific Session[@ref99]. This trial, which randomized patients with high on-treatment platelet reactivity undergoing PCI to receive either standard clopidogrel dosing or the novel, more potent P2Y12 receptor antagonist, prasugrel (10 mg daily), was terminated early due to a paucity of clinical events. After 6 months, only one clinical endpoint, a periprocedural MI, was observed.

Both the GRAVITAS and TRIGGER PCI trials have important limitations to keep in mind when analyzing the impact of platelet function testing in coronary interventions. In the GRAVITAS trial, event rates for both the standard and high clopidogrel dosing groups were significantly lower than predicted, which led to underpowering for the composite endpoint of death, MI or ST. Additionally, the TRIGGER PCI trial was stopped after only one clinical event was observed at the time of the first interim analysis. These findings suggest that higher risk patients, such as those undergoing complicated or unsuccessful PCI procedures, were excluded from enrollment in the GRAVITAS and TRIGGER PCI trials. The follow up duration in these studies were also likely too short to identify clinically meaningful differences in endpoints. In the patient level meta-analysis by Brar and colleagues, Kaplan-Meier curves did not appear to diverge until after 180 days[@ref98]. Endpoints from the GRAVITAS and TRIGGER PCI trials were obtained at 180 days, which may be too early to detect significant differences in event rates. These observations suggest that the design of future trials assessing the modification of antiplatelet therapy based on platelet function testing, should consider larger cohorts, longer follow up duration and the recruitment of higher-risk patients.

Analogous to INR monitoring for warfarin treatment, there may be a therapeutic range which best balances the efficacy and safety of dual antiplatelet therapy after PCI. The Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty- Platelet Reactivity Predicts Outcome (ARMYDA-PRO) trial and other studies have established efficacy thresholds of platelet inhibition to minimize cardiac events after coronary interventions (240 PRU by the VerifyNow assay)[@ref100]--[@ref103]. These values are similar to the 230 PRU cut-off identified by Brar and colleagues in the previously mentioned patient-level meta-analysis[@ref99]. In the future, platelet function testing may be used to identify individuals who are poor metabolizers of clopidogrel and therefore, at increased risk for adverse cardiovascular events. Conversely, testing could identify individuals with an enhanced clopidogrel response, which could lead to increased bleeding complications. Results from ARMYDA study group noted that the 30 day incidence of major bleeding was directly related to pre-PCI platelet reactivity. Using the VerifyNow P2Y12 assay, patients within the lowest quartile of platelet reactivity (high clopidogrel responsiveness) were at 4.5-fold increased risk of major bleeding when compared to the highest quartile of platelet reactivity (lowest clopidogrel responsiveness)[@ref104]. Using these studies, there may be an ideal range for platelet reactivity that maximizes the benefits while minimizing the risks of antiplatelet therapy after coronary stenting. Additional research is necessary to better understand and incorporate the data from genetic and platelet function testing into clinical practice.

DES in acute myocardial infarction {#sec1-8}
==================================

Based on the findings from the landmark SIRIUS and TAXUS IV trials, the FDA initially approved the use of DES for discrete, *de novo* lesions in native coronary vessels with diameters of 2.5 to 3.5 mm[@ref105][@ref106]. As more data demonstrating the efficacy of DES became available, the use of this technology for more diverse patient populations and clinical situations rapidly increased. Many of these applications were for "off-label" indications, including the treatment of ACS. There have been concerns however, that the use of DES in this setting may be associated with higher risks of ST[@ref61][@ref107][@ref108]. Some of the proposed mechanisms for this phenomenon relate to possible stent placement within a necrotic arterial wall core, thrombus trapping behind the stent struts, delayed endothelialization due to the anti-restenotic drug or significantly increased risks associated with discontinuing dual antiplatelet therapy after acute myocardial infarction[@ref6]. Although the benefits of DES for FDA-approved indications are well established, whether this applies for primary PCI, particularly in the setting of ST-segment myocardial infarction (STEMI) remains controversial.

As the pivotal DES approval trials excluded patients with AMI, clinical data regarding procedural choices and outcomes remain limited. Previous registry and randomized trials comparing DES to BMS in STEMI, have reported conflicting results regarding late safety profiles and other clinical outcomes. The GRACE (Global Registry of Acute Coronary Events) study, which collected data on 5093 patients with STEMI, reported higher mortality associated with DES compared to BMS during 6 month to 2 year follow up (HR 4.9; *P*=0.01)[@ref109]. These observations of increased late mortality with DES questioned the safety of DES during STEMI and led to randomized trials addressing these concerns. The TYPHOON (Trial to Assess the Use of Cypher Sirolimus-Eluting Coronary Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty) trial, randomized 712 patients presenting with STEMI to either SES or BMS during primary PCI. At 4 year follow up, the SES group demonstrated significantly better freedom from TLR (92.4 vs. 85.1%; *P*=0.002). There was additionally no significant difference in freedom from cardiac death (97.6 vs. 95.9%; *P*=0.37), freedom from repeat MI (94.8 vs. 95.6%; *P*= 0.85) or definite/probable ST (4.4 vs. 4.8%; *P*=0.83)[@ref110]. The 5 year follow up data from the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial also demonstrated no significant difference in MACE between PES and BMS[@ref108]. This trial, which randomized 619 patients to either PES or BMS at the time of primary PCI, noted no significant difference in the composite of cardiac death, recurrent MI or TLR (18.6 vs. 21.8%; HR 0.82; 95% CI: 0.58-1.18; *P*=0.28) or definite/probable ST (4.2 vs. 3.4%; HR 1.19; 95% CI: 0.51-276; *P*= 0.68)[@ref111]. These results differ from the results reported in the DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) trial, which randomized 626 patients presenting with STEMI to receive either DES (SES, PES or ZES) or BMS with or without distal protection during primary PCI. At 3 year follow up, the DES group demonstrated significantly better rates of TLR (6.1 vs. 16.3%; *P*\<0.001) but increased rates of cardiac death (6.1 vs. 1.9%; *P*=0.01) compared to the BMS group[@ref113].

The conflicting results of these trials could be related to limitations arising from the relatively small study sizes and subsequent underpowering to detect low frequency adverse events. The largest randomized trial to date, the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial randomized 3006 patients presenting with STEMI to receive either PES or BMS during primary PCI[@ref13]. At 12 month follow up, patients who received PES had significantly lower rates of ischaemia-driven TLR (4.5 vs. 7.5%; HR 0.59; 95% CI: 0.43-0.83; *P*=0.002) and TVR (5.8 vs. 8.7%; HR 0.69; 95% CI: 0.48-0.89; *P*=0.006) when compared to BMS. Additionally, there was no significant difference in the primary safety endpoint of death, MI, stroke or ST (PES 8.1 vs. BMS 8.0%; HR 1.02; 95% CI: 0.76-1.36; *P*=0.92), rates of death or re-infarction (PES 6.8 vs. BMS 7.9%; HR 0.97; 95% CI: 0.7-1.32; *P*=0.83) and ST (PES 3.2 vs. BMS 3.4%; HR 0.93; 95% CI: 0.59-1.47; *P*=0.77) ([Fig. 4](#F4){ref-type="fig"}). These results were confirmed at 3 year follow up, with patients who received PES demonstrating significantly lower rates of ischaemia driven TLR (9.4 vs. 15.1%; HR 0.60; 95% CI: 0.48-0.76; *P*\<0.0001) compared to BMS. Rates of all-cause mortality (PES 5.6 vs. BMS 6.6%; HR 0.84; 95% CI: 0.6-1.17; *P*=0.31) and definite or probable ST (PES 4.8 vs. BMS 4.3%; HR 1.10; HR 1.10; 95% CI: 0.74-1.65; *P*=0.63) were similar in both the PES and BMS cohorts at 3 year follow up[@ref113].

![Twelve month event rates in patients with STEMI treated with PES and BMS from the HORIZONS-AMI trial. *Source*: [@ref13].](IJMR-136-926-g004){#F4}

To better compare the efficacy and safety of DES in STEMI, Kastrati and colleagues performed a meta-analysis, which identified eight randomized trials consisting of 2786 patients[@ref114]. After a mean follow up of 12 to 24.2 months, patients treated with DES compared to BMS, demonstrated better rates of TLR (HR 0.38; 95% CI: 0.29-0.50; *P*\<0.001), with no significant difference in death (HR 0.76; 95% CI: 0.53-1.10; *P*=0.14), recurrent MI (HR 0.72; 95% CI: 0.48-1.08; *P*=0.11) or ST (HR 0.80; 95% CI: 0.46-1.39; *P*=0.43). A more recent and larger meta-analysis was conducted by Brar and colleagues[@ref113], which included 13 randomized trials consisting of 7352 patients and 18 registry studies consisting of 26,521 patients[@ref115]. At a maximum follow-up of 2 years, patients treated with DES compared to BMS, demonstrated a significantly reduced need for repeat revascularization (5.3 vs. 11.5%; RR 0.44; 95% CI: 0.35-0.55; *P*\<0.001). Additionally, there were no significant differences in terms of mortality (3.7 vs. 4.3%; RR 0.89; 95% CI: 0.70-1.14; *P*=0.36) or definite/probable ST (2.7 vs. 2.6%; RR 0.96; 95% CI: 0.72-1.30; *P*=0.81) between the DES and BMS, out to 2 years of follow up. Based on these recently published randomized trials and meta-analyses, DES in the setting of AMI, particularly STEMI, appears both safe and efficacious when compared to BMS.

Based on these findings, on February 22, 2012, the FDA approved both the Taxus Liberte (Boston Scientific) and Taxus ION (Boston Scientific) stents for the treatment of patients presenting with AMI[@ref116]. Initially approved in 2009 for use in *de novo*, native vessel coronary lesions, the Taxus Liberte PES, offers thinner struts and a continuous cell architecture that provides a lower profile and greater flexibility[@ref117][@ref118]. The Taxus ION PES on the other hand, was approved in 2011 and is composed of a novel PtCr stent platform that offers increased strength, deliverability and visibility compared to steal or cobalt alloys[@ref119]. The Taxus Liberte PES and Taxus ION PES are currently the only stents in the U.S. with an approved indication for AMI. Future studies with longer follow up and involving the newer generation DES are required to determine the stability and strength of these findings.

Conclusions {#sec1-9}
===========

DES have transformed the field of cardiology, allowing for higher risk coronary interventions and an alternative for patients who would otherwise require coronary artery bypass surgery. These stents provide advantages over BMS in the area of improved TLR and decreased rates of repeat revascularization. Some of the concerns and controversies surrounding DES involve the long-term risk of restenosis and ST, especially after DAPT is interrupted. Current and future technology, including the newer generation EES and ZES, biodegradable polymers and even completely biodegradable stents offer the potential for improvement in the care of patients undergoing coronary stenting. Additional areas including "off-label" indications, platelet reactivity assays and genetic testing to detect CYP2C19 polymorphisms have the potential to maximize the benefits of DES while minimizing the risks.
